Cell therapy company picks Durham for 200 jobs, after securing incentive from NC

SourceThe News & Observer
Date Published05/20/2021
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name CARsgen Therapeutics Corp.
Parent companyCARsgen Therapeutics Holdings Limited
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):200
Year reshoring announced:2021
Year reshoring implemented or to be implemented:2022
Domestically, the work will be done:In-house
Capital investment ($):157
Country(ies) from which reshored:China
City reshored to:Durham
State(s) reshored to:NC
If relevant, work nearshored to:-
Product(s) reshoredchimeric antigen receptor (CAR) T cell therapies
What domestic positive factors made reshoring more attractive?Government Incentives, Impact on domestic economy, Skilled workforce availability/training
Government Incentive dollar amount:$3.4 million
Find Reshoring Articles